Humana Inc has a consensus price target of $458.34 based on the ratings of 31 analysts. The high is $640 issued by SVB Leerink on November 3, 2022. The low is $310 issued by Barclays on April 2, 2024. The 3 most-recent analyst ratings were released by TD Cowen, Cantor Fitzgerald, and Truist Securities on July 24, 2024, July 23, 2024, and July 15, 2024, respectively. With an average price target of $389 between TD Cowen, Cantor Fitzgerald, and Truist Securities, there's an implied -0.92% downside for Humana Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/24/2024 | Buy Now | 3.66% | TD Cowen | Gary Taylor | $396 → $407 | Maintains | Buy | Get Alert |
07/23/2024 | Buy Now | -8.31% | Cantor Fitzgerald | Sarah James | $360 → $360 | Reiterates | Neutral → Neutral | Get Alert |
07/15/2024 | Buy Now | 1.88% | Truist Securities | David Macdonald | $355 → $400 | Maintains | Hold | Get Alert |
06/26/2024 | Buy Now | -0.16% | Piper Sandler | Jessica Tassan | → $392 | Initiates | → Overweight | Get Alert |
06/24/2024 | Buy Now | -4.74% | Morgan Stanley | Erin Wright | → $374 | Initiates | → Equal-Weight | Get Alert |
06/12/2024 | Buy Now | -8.31% | Cantor Fitzgerald | Sarah James | $360 → $360 | Reiterates | Neutral → Neutral | Get Alert |
05/30/2024 | Buy Now | -4.74% | Baird | Michael Ha | → $374 | Initiates | → Neutral | Get Alert |
05/20/2024 | Buy Now | -4.24% | B of A Securities | Kevin Fischbeck | $342 → $376 | Maintains | Neutral | Get Alert |
04/25/2024 | Buy Now | -10.09% | RBC Capital | Frank Morgan | $415 → $353 | Maintains | Outperform | Get Alert |
04/25/2024 | Buy Now | -16.97% | UBS | Kevin Caliendo | $334 → $326 | Maintains | Neutral | Get Alert |
04/25/2024 | Buy Now | -8.31% | Cantor Fitzgerald | Sarah James | $391 → $360 | Maintains | Neutral | Get Alert |
04/25/2024 | Buy Now | -5.76% | Oppenheimer | Michael Wiederhorn | $415 → $370 | Maintains | Outperform | Get Alert |
04/22/2024 | Buy Now | -2.96% | Jefferies | David Windley | $411 → $381 | Maintains | Buy | Get Alert |
04/10/2024 | Buy Now | -0.42% | Cantor Fitzgerald | Sarah James | → $391 | Reiterates | Neutral → Neutral | Get Alert |
04/08/2024 | Buy Now | -10.86% | Wells Fargo | Stephen Baxter | $413 → $350 | Maintains | Overweight | Get Alert |
04/04/2024 | Buy Now | -0.42% | Cantor Fitzgerald | Sarah James | → $391 | Reiterates | Neutral → Neutral | Get Alert |
04/03/2024 | Buy Now | -1.94% | Goldman Sachs | Nathan Rich | $450 → $385 | Maintains | Buy | Get Alert |
04/02/2024 | Buy Now | -21.05% | Barclays | Andrew Mok | $356 → $310 | Maintains | Equal-Weight | Get Alert |
04/02/2024 | Buy Now | 0.86% | TD Cowen | Gary Taylor | $427 → $396 | Maintains | Buy | Get Alert |
04/02/2024 | Buy Now | -12.9% | B of A Securities | Kevin Fischbeck | $470 → $342 | Downgrade | Buy → Neutral | Get Alert |
03/22/2024 | Buy Now | — | Raymond James | John Ransom | — | Initiates | → Market Perform | Get Alert |
03/13/2024 | Buy Now | — | Argus Research | David Toung | — | Downgrade | Buy → Hold | Get Alert |
03/06/2024 | Buy Now | -9.33% | Barclays | Andrew Mok | → $356 | Initiates | → Equal-Weight | Get Alert |
01/30/2024 | Buy Now | 5.19% | Wells Fargo | Stephen Baxter | $465 → $413 | Maintains | Overweight | Get Alert |
01/29/2024 | Buy Now | 14.61% | Goldman Sachs | Nathan Rich | $515 → $450 | Maintains | Buy | Get Alert |
01/26/2024 | Buy Now | 1.88% | Mizuho | Ann Hynes | $550 → $400 | Maintains | Buy | Get Alert |
01/26/2024 | Buy Now | -0.42% | Cantor Fitzgerald | Sarah James | $597 → $391 | Downgrade | Overweight → Neutral | Get Alert |
01/26/2024 | Buy Now | 9.52% | Stephens & Co. | Scott Fidel | $550 → $430 | Maintains | Overweight | Get Alert |
01/26/2024 | Buy Now | -5.76% | UBS | Kevin Caliendo | $530 → $370 | Downgrade | Buy → Neutral | Get Alert |
01/26/2024 | Buy Now | 5.7% | RBC Capital | Ben Hendrix | $507 → $415 | Maintains | Outperform | Get Alert |
01/26/2024 | Buy Now | 14.61% | Goldman Sachs | Nathan Rich | $515 → $450 | Maintains | Buy | Get Alert |
01/25/2024 | Buy Now | -8.31% | Deutsche Bank | George Hill | $595 → $360 | Downgrade | Buy → Hold | Get Alert |
01/19/2024 | Buy Now | 40.08% | Truist Securities | David Macdonald | → $550 | Reiterates | Hold → Hold | Get Alert |
01/19/2024 | Buy Now | 52.05% | Cantor Fitzgerald | Sarah James | → $597 | Reiterates | Overweight → Overweight | Get Alert |
01/19/2024 | Buy Now | 29.13% | RBC Capital | Ben Hendrix | $599 → $507 | Maintains | Outperform | Get Alert |
01/19/2024 | Buy Now | 31.17% | Goldman Sachs | Nathan Rich | $595 → $515 | Maintains | Buy | Get Alert |
01/17/2024 | Buy Now | 60.46% | Oppenheimer | Michael Wiederhorn | → $630 | Reiterates | Outperform → Outperform | Get Alert |
12/12/2023 | Buy Now | 40.08% | Argus Research | David Toung | → $550 | Upgrade | Hold → Buy | Get Alert |
11/21/2023 | Buy Now | 52.05% | Cantor Fitzgerald | Sarah James | → $597 | Reiterates | Overweight → Overweight | Get Alert |
11/17/2023 | Buy Now | 46.45% | JP Morgan | Lisa Gill | $593 → $575 | Maintains | Neutral | Get Alert |
11/02/2023 | Buy Now | 52.56% | RBC Capital | Ben Hendrix | $594 → $599 | Maintains | Outperform | Get Alert |
11/02/2023 | Buy Now | 45.17% | Stephens & Co. | Scott Fidel | $575 → $570 | Maintains | Overweight | Get Alert |
11/02/2023 | Buy Now | 52.05% | Cantor Fitzgerald | Sarah James | → $597 | Reiterates | Overweight → Overweight | Get Alert |
10/09/2023 | Buy Now | 49.25% | Jefferies | David Windley | $580 → $586 | Maintains | Buy | Get Alert |
09/14/2023 | Buy Now | 52.05% | Cantor Fitzgerald | Sarah James | → $597 | Reiterates | Overweight → Overweight | Get Alert |
08/30/2023 | Buy Now | 58.93% | Morgan Stanley | Michael Ha | $637 → $624 | Maintains | Overweight | Get Alert |
08/15/2023 | Buy Now | 56.13% | TD Cowen | Gary Taylor | $616 → $613 | Maintains | Outperform | Get Alert |
08/08/2023 | Buy Now | 52.56% | Bernstein | Lance Wilkes | $568 → $599 | Maintains | Market Perform | Get Alert |
08/07/2023 | Buy Now | 59.95% | Deutsche Bank | George Hill | $468 → $628 | Maintains | Buy | Get Alert |
08/03/2023 | Buy Now | 40.08% | Truist Securities | David Macdonald | $530 → $550 | Maintains | Hold | Get Alert |
08/03/2023 | Buy Now | 51.29% | RBC Capital | Ben Hendrix | $637 → $594 | Maintains | Outperform | Get Alert |
08/03/2023 | Buy Now | 42.63% | Stephens & Co. | Scott Fidel | $555 → $560 | Maintains | Overweight | Get Alert |
07/14/2023 | Buy Now | 62.24% | Morgan Stanley | Michael Ha | $637 → $637 | Reiterates | Overweight → Overweight | Get Alert |
07/13/2023 | Buy Now | 42.63% | UBS | Kevin Caliendo | $620 → $560 | Maintains | Buy | Get Alert |
07/13/2023 | Buy Now | 37.79% | Wells Fargo | Stephen Baxter | $610 → $541 | Maintains | Overweight | Get Alert |
07/11/2023 | Buy Now | 40.08% | Mizuho | Ann Hynes | $615 → $550 | Maintains | Buy | Get Alert |
07/07/2023 | Buy Now | 37.53% | JP Morgan | Lisa Gill | $576 → $540 | Downgrade | Overweight → Neutral | Get Alert |
06/23/2023 | Buy Now | — | Argus Research | David Toung | — | Downgrade | Buy → Hold | Get Alert |
06/20/2023 | Buy Now | 34.99% | Truist Securities | David Macdonald | $590 → $530 | Maintains | Hold | Get Alert |
06/20/2023 | Buy Now | 62.24% | RBC Capital | Ben Hendrix | → $637 | Reiterates | Outperform → Outperform | Get Alert |
06/15/2023 | Buy Now | 62.24% | RBC Capital | Ben Hendrix | → $637 | Reiterates | Outperform → Outperform | Get Alert |
05/30/2023 | Buy Now | 46.7% | JP Morgan | Lisa Gill | $625 → $576 | Maintains | Overweight | Get Alert |
05/02/2023 | Buy Now | 56.89% | TD Cowen | Gary Taylor | $581 → $616 | Maintains | Outperform | Get Alert |
04/27/2023 | Buy Now | 52.82% | SVB Securities | Whit Mayo | $640 → $600 | Maintains | Outperform | Get Alert |
04/27/2023 | Buy Now | 50.27% | Stephens & Co. | Scott Fidel | → $590 | Reiterates | → Overweight | Get Alert |
04/27/2023 | Buy Now | 62.24% | RBC Capital | Ben Hendrix | → $637 | Reiterates | → Outperform | Get Alert |
04/27/2023 | Buy Now | 60.46% | Oppenheimer | Michael Wiederhorn | → $630 | Reiterates | → Outperform | Get Alert |
04/21/2023 | Buy Now | 52.05% | Cantor Fitzgerald | Sarah James | → $597 | Initiates | → Overweight | Get Alert |
04/13/2023 | Buy Now | 50.27% | Truist Securities | David Macdonald | $560 → $590 | Maintains | Hold | Get Alert |
04/11/2023 | Buy Now | 62.24% | Morgan Stanley | Michael Ha | $620 → $637 | Maintains | Overweight | Get Alert |
02/28/2023 | Buy Now | 43.14% | Deutsche Bank | George Hill | $575 → $562 | Maintains | Buy | Get Alert |
02/07/2023 | Buy Now | 42.63% | Truist Securities | David Macdonald | $580 → $560 | Maintains | Hold | Get Alert |
02/06/2023 | Buy Now | 47.98% | Cowen & Co. | Gary Taylor | $647 → $581 | Maintains | Outperform | Get Alert |
02/06/2023 | Buy Now | 46.45% | Credit Suisse | A.J. Rice | $635 → $575 | Maintains | Outperform | Get Alert |
02/03/2023 | Buy Now | 50.27% | Stephens & Co. | Scott Fidel | $665 → $590 | Maintains | Overweight | Get Alert |
02/02/2023 | Buy Now | 57.91% | UBS | Kevin Caliendo | $645 → $620 | Maintains | Buy | Get Alert |
01/06/2023 | Buy Now | 59.18% | JP Morgan | Lisa Gill | $630 → $625 | Maintains | Overweight | Get Alert |
12/13/2022 | Buy Now | 66.06% | Goldman Sachs | Nathan Rich | $575 → $652 | Upgrade | Neutral → Buy | Get Alert |
11/10/2022 | Buy Now | 56.64% | Mizuho | Ann Hynes | $529 → $615 | Maintains | Buy | Get Alert |
11/03/2022 | Buy Now | 46.45% | Goldman Sachs | Nathan Rich | $522 → $575 | Maintains | Neutral | Get Alert |
11/03/2022 | Buy Now | 62.24% | RBC Capital | Ben Hendrix | $560 → $637 | Maintains | Outperform | Get Alert |
11/03/2022 | Buy Now | 61.73% | Credit Suisse | Jonathan Yong | $548 → $635 | Maintains | Outperform | Get Alert |
11/03/2022 | Buy Now | 63% | SVB Leerink | Whit Mayo | $540 → $640 | Maintains | Outperform | Get Alert |
10/31/2022 | Buy Now | 57.91% | Morgan Stanley | Ricky Goldwasser | $549 → $620 | Maintains | Overweight | Get Alert |
10/26/2022 | Buy Now | 46.7% | Deutsche Bank | George Hill | → $576 | Upgrade | Hold → Buy | Get Alert |
09/20/2022 | Buy Now | 38.55% | RBC Capital | Frank Morgan | $541 → $544 | Maintains | Outperform | Get Alert |
09/20/2022 | Buy Now | 39.83% | Morgan Stanley | Ricky Goldwasser | $494 → $549 | Upgrade | Equal-Weight → Overweight | Get Alert |
09/16/2022 | Buy Now | 45.17% | Truist Securities | David Macdonald | $550 → $570 | Maintains | Hold | Get Alert |
09/16/2022 | Buy Now | 40.08% | Oppenheimer | Michael Wiederhorn | $520 → $550 | Maintains | Outperform | Get Alert |
08/02/2022 | Buy Now | 25.82% | Morgan Stanley | Ricky Goldwasser | $453 → $494 | Maintains | Equal-Weight | Get Alert |
07/28/2022 | Buy Now | 45.17% | Barclays | Steve Valiquette | $500 → $570 | Maintains | Overweight | Get Alert |
07/28/2022 | Buy Now | 34.73% | Mizuho | Ann Hynes | $500 → $529 | Maintains | Buy | Get Alert |
07/28/2022 | Buy Now | 32.44% | Oppenheimer | Michael Wiederhorn | $510 → $520 | Maintains | Outperform | Get Alert |
07/28/2022 | Buy Now | 37.53% | SVB Leerink | Whit Mayo | $535 → $540 | Maintains | Outperform | Get Alert |
07/14/2022 | Buy Now | 40.08% | Truist Securities | David Macdonald | $490 → $550 | Maintains | Hold | Get Alert |
06/17/2022 | Buy Now | 29.89% | Loop Capital | Joseph France | → $510 | Initiates | → Buy | Get Alert |
05/25/2022 | Buy Now | 30.91% | Wells Fargo | Stephen Baxter | $512 → $514 | Maintains | Overweight | Get Alert |
04/28/2022 | Buy Now | 30.4% | Wells Fargo | Stephen Baxter | $491 → $512 | Maintains | Overweight | Get Alert |
04/28/2022 | Buy Now | 37.79% | RBC Capital | Ben Hendrix | $525 → $541 | Maintains | Outperform | Get Alert |
04/28/2022 | Buy Now | 36.26% | SVB Leerink | Whit Mayo | $525 → $535 | Maintains | Outperform | Get Alert |
The latest price target for Humana (NYSE:HUM) was reported by TD Cowen on July 24, 2024. The analyst firm set a price target for $407.00 expecting HUM to rise to within 12 months (a possible 3.66% upside). 52 analyst firms have reported ratings in the last year.
The latest analyst rating for Humana (NYSE:HUM) was provided by TD Cowen, and Humana maintained their buy rating.
The last upgrade for Humana Inc happened on December 12, 2023 when Argus Research raised their price target to $550. Argus Research previously had a hold for Humana Inc.
The last downgrade for Humana Inc happened on April 2, 2024 when B of A Securities changed their price target from $470 to $342 for Humana Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humana, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humana was filed on July 24, 2024 so you should expect the next rating to be made available sometime around July 24, 2025.
While ratings are subjective and will change, the latest Humana (HUM) rating was a maintained with a price target of $396.00 to $407.00. The current price Humana (HUM) is trading at is $392.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.